Business Combinations and Asset Purchases (Narrative) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Jan. 02, 2022 USD ($) employees $ / shares shares	Jan. 03, 2021 USD ($) employees $ / shares	Dec. 29, 2019 USD ($)	Sep. 17, 2021 $ / shares
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability, Current	$ (1,300)	$ (2,900)
Business Combination, Contingent Consideration, Liability, Noncurrent	56,700	100
Business Combination, Contingent Consideration, Liability, Total	$ (58,000)	(3,000)
Business Combination, Contingent Consideration Arrangements, Maximum Period	6 years 10 months 24 days
Goodwill	$ 7,416,584	3,447,114	$ 3,111,227
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions	1 year
Business Combination, Contingent Consideration Arrangements, Weighted Average Period	5 years 4 months 24 days
Business Combination, Acquisition Related Costs	$ 97,500	$ 9,300	6,600
Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Entity Number of Employees | employees		400
Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets		$ 35,532
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		20,302
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		18,114
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		412,097
Business Acquisition, Cost of Acquired Entity, Cash Paid		437,661
Business Combination, Consideration Transferred, Liabilities Incurred		$ 1,660
Weighted average amortization period (in years)		11 years
Goodwill		$ 221,751
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total		(25,674)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue		2,031
Working capital and other adjustments		(384)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt		(46,430)
Cash Acquired		26,840
Business Combination, Consideration Transferred		412,097
Interest Expense		500
Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			62,756
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			(3,404)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			11,840
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			626
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			417,072
Business Acquisition, Cost of Acquired Entity, Cash Paid			409,837
Business Combination, Consideration Transferred, Liabilities Incurred			$ 7,084
Weighted average amortization period (in years)			11 years
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value			$ (12,734)
Goodwill			169,108
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total			(63,113)
Working capital and other adjustments			3,401
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			(26,718)
Cash Acquired			15,984
Business Combination, Consideration Transferred			417,072
Shandong Meizheng [Member]
Business Acquisition [Line Items]
Compensation Expense, Excluding Cost of Good and Service Sold	$ 14,300	4,700
Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax			2,600
Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Compensation Expense, Excluding Cost of Good and Service Sold			500
Oxford Immunotec
Business Acquisition [Line Items]
Entity Number of Employees | employees	275
Nexcelom Bioscience
Business Acquisition [Line Items]
Entity Number of Employees | employees	130
BioLegend [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue	$ 5,295,483	4,024,631
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets	184,704
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	147,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	9,330
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	5,688,964
Business Acquisition, Cost of Acquired Entity, Cash Paid	3,336,115
Business Combination, Consideration Transferred, Liabilities Incurred	$ 6,857
Weighted average amortization period (in years)	16 years 3 months 18 days
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual	$ 91,700
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual	25,800
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	0
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	$ 0	183
Entity Number of Employees | employees	700
Goodwill	$ 3,510,710
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total	(668,920)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	(38,239)
Cash Acquired from Acquisition	292,400
Cash Acquired	(292,377)
Business Combination, Consideration Transferred	5,688,964
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax	$ 1,001,109	$ 551,572
Business Acquisition, Pro Forma Earnings Per Share, Basic | $ / shares	$ 7,690	$ 4,390
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ / shares	$ 7,660	$ 4,370
Foreign Currency Transaction Gain (Loss), before Tax	$ (5,400)
Interest Expense	23,400
Cash Acquired from Acquisition	(292,400)
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Common Stock	$ 2,600,000
Business Acquisition, Share Price | $ / shares				$ 187.56
Stock Issued During Period, Shares, Acquisitions | shares	14,066,799
Business Combination, Acquisition Related Costs, Excluded From Proforma Income (Loss) From Continuing Operations	$ 43,200
Business Combination, Bridge Financing and Debt Pre-issuance Hedging Costs, Excluded From Proforma Income (Loss) From Continuing Operations	23,300
Business Combination, Pro Forma Information, Amortization of Acquired Intangible Assets	47,000
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Cash	3,300,000
Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets		$ 72,826
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		(4,628)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		26,507
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		15,564
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		994,098
Business Acquisition, Cost of Acquired Entity, Cash Paid	1,128,584
Business Combination, Consideration Transferred, Liabilities Incurred	$ 2,910
Weighted average amortization period (in years)	12 years 4 months 24 days
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	$ (57,431)
Goodwill		547,388
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total		(83,931)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue		1,197
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt		(58,920)
Cash Acquired	(195,010)
Business Combination, Consideration Transferred	994,098
Biosense, Sirion and Qognit [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	108,400
Core Technology [Member] | Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		65,730
Core Technology [Member] | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			153,267
Trade Names [Member] | Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		5,580
Trade Names [Member] | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			11,210
Customer Relationships [Member] | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			101,500
In Process Research and Development [Member] | Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		10,700
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,970,350	1,691,227	1,612,407
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	5,446,234	1,755,887	1,498,820
United States of America, Dollars | Fiscal Year 2021 Other Acquisitions
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	331,000
Business Combinations, Identifiable Intangible Assets Acquired	500,000
United States of America, Dollars | Fiscal Year 2020 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments		39,100
United States of America, Dollars | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments		399,800
United States of America, Dollars | Fiscal Year 2020 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments		438,900
United States of America, Dollars | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			433,100
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			31,800
United States of America, Dollars | Fiscal Year 2019 Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			46,600
United States of America, Dollars | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			166,500
United States of America, Dollars | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			$ 219,900
United States of America, Dollars | Oxford Immunotec
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	590,900
United States of America, Dollars | Nexcelom Bioscience
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	267,300
United States of America, Dollars | BioLegend [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	5,700,000
United States of America, Dollars | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	1,200,000
Business Combinations, Identifiable Intangible Assets Acquired	2,500,000
United States of America, Dollars | Core Technology [Member] | Fiscal Year 2021 Acquisitions
Business Acquisition [Line Items]
Business Combinations, Identifiable Intangible Assets Acquired	1,100,000
United States of America, Dollars | Customer Relationships [Member] | Fiscal Year 2021 Acquisitions
Business Acquisition [Line Items]
Business Combinations, Identifiable Intangible Assets Acquired	$ 1,900,000
United Kingdom, Pounds | Horizon Discovery Group plc [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments		$ 296,000